Type(s) of targeted therapy-Ibrutinib Posts on Medivizor
Navigation Menu

Type(s) of targeted therapy-Ibrutinib Posts on Medivizor

Evaluating the risk of infection associated with ibrutinib treatment in patients with B-cell lymphoma

Posted by on Mar 20, 2020 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study aimed to investigate the risk of infection with ibrutinib treatment in B-cell malignancies such as lymphoma.  This study concluded that ibrutinib was associated with a higher risk of infections in these patients. Some background B-cell malignancies such as non-Hodgkin lymphoma (NHL) lead to an increased risk of...

Read More

Searching for patients with relapsed or unresponsive small lymphocytic lymphoma to test an immune cell-stimulating treatment

Posted by on Dec 19, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study is looking for patients with relapsed or unresponsive chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) to test IOV-2001, a treatment that boosts cancer-killing immune cells.  The main outcome that will be measured is how well patients respond to treatment. This study is recruiting in Columbus, OH, the...

Read More

Serious infections in patients receiving ibrutinib for the treatment of leukemia and lymphoma

Posted by on Sep 27, 2018 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study looked at the risk of infections associated with ibrutinib (Imbruvica) used in the treatment of leukemia and lymphoma. Researchers found that patients receiving ibrutinib are at risk of serious infections. Some background Ibrutinib is a drug which targets certain proteins on cancer cells to stop them from working. It is often...

Read More

Long-term outcomes of ibrutinib plus rituximab for relapsed or refractory mantle cell lymphoma

Posted by on Jun 9, 2018 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study investigated the long-term safety and effectiveness of ibrutinib (Imbruvica) plus rituximab (Rituxan) for relapsed or refractory (does not respond to treatment) mantle cell lymphoma. This study concluded that this treatment is safe and effective for relapsed or refractory mantle cell lymphoma. Some background Mantle cell...

Read More

Does ibrutinib pre-treatment affect the outcomes of alloHCT for patients with CLL?

Posted by on May 31, 2018 in Leukemia | 0 comments

In a nutshell This study investigated the safety and effectiveness of alloHCT (allogeneic hematopoietic stem cell transplantation) in patients with chronic lymphocytic leukemia (CLL) pre-treated with ibrutinib (Imbruvica). This study concluded that ibrutinib does not affect the safety of alloHCT. Some background Ibrutinib has become the standard of...

Read More